Although several drugs are at the late stage of clinical development, NASH therapy is still based on lifestyle adjustment (diet, exercise, etc.)and the prescription of medicines improving lipid metabolism, enhancing sensitivity to insulin, balancing oxidation, and counteracting fibrosis. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.